Sartorius Stedim Biotech Statistics
Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of EUR 16.35 billion. The enterprise value is 18.74 billion.
Market Cap | 16.35B |
Enterprise Value | 18.74B |
Important Dates
The next estimated earnings date is Tuesday, January 28, 2025.
Earnings Date | Jan 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Sartorius Stedim Biotech has 97.31 million shares outstanding. The number of shares has increased by 3.60% in one year.
Current Share Class | n/a |
Shares Outstanding | 97.31M |
Shares Change (YoY) | +3.60% |
Shares Change (QoQ) | +3.02% |
Owned by Insiders (%) | 0.00% |
Owned by Institutions (%) | 11.84% |
Float | 29.47M |
Valuation Ratios
The trailing PE ratio is 99.91 and the forward PE ratio is 40.96. Sartorius Stedim Biotech's PEG ratio is 1.97.
PE Ratio | 99.91 |
Forward PE | 40.96 |
PS Ratio | 5.86 |
PB Ratio | 4.22 |
P/TBV Ratio | n/a |
P/FCF Ratio | 32.47 |
P/OCF Ratio | n/a |
PEG Ratio | 1.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.94, with an EV/FCF ratio of 37.20.
EV / Earnings | 116.68 |
EV / Sales | 6.85 |
EV / EBITDA | 27.94 |
EV / EBIT | 46.98 |
EV / FCF | 37.20 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.72.
Current Ratio | 2.14 |
Quick Ratio | 1.05 |
Debt / Equity | 0.72 |
Debt / EBITDA | 4.22 |
Debt / FCF | 5.62 |
Interest Coverage | 1.85 |
Financial Efficiency
Return on equity (ROE) is 5.02% and return on invested capital (ROIC) is 3.78%.
Return on Equity (ROE) | 5.02% |
Return on Assets (ROA) | 3.12% |
Return on Capital (ROIC) | 3.78% |
Revenue Per Employee | 271,325 |
Profits Per Employee | 15,929 |
Employee Count | 10,662 |
Asset Turnover | 0.34 |
Inventory Turnover | 1.78 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.06% in the last 52 weeks. The beta is 0.67, so Sartorius Stedim Biotech's price volatility has been lower than the market average.
Beta (5Y) | 0.67 |
52-Week Price Change | -16.06% |
50-Day Moving Average | 184.30 |
200-Day Moving Average | 198.99 |
Relative Strength Index (RSI) | 35.70 |
Average Volume (20 Days) | 63,610 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of EUR 2.74 billion and earned 160.60 million in profits. Earnings per share was 1.68.
Revenue | 2.74B |
Gross Profit | 1.19B |
Operating Income | 398.90M |
Pretax Income | 224.60M |
Net Income | 160.60M |
EBITDA | 645.70M |
EBIT | 398.90M |
Earnings Per Share (EPS) | 1.68 |
Balance Sheet
The company has 482.60 million in cash and 2.83 billion in debt, giving a net cash position of -2.35 billion or -24.14 per share.
Cash & Cash Equivalents | 482.60M |
Total Debt | 2.83B |
Net Cash | -2.35B |
Net Cash Per Share | -24.14 |
Equity (Book Value) | 3.94B |
Book Value Per Share | 39.78 |
Working Capital | 862.60M |
Cash Flow
In the last 12 months, operating cash flow was 866.30 million and capital expenditures -362.60 million, giving a free cash flow of 503.70 million.
Operating Cash Flow | 866.30M |
Capital Expenditures | -362.60M |
Free Cash Flow | 503.70M |
FCF Per Share | 5.18 |
Margins
Gross margin is 43.33%, with operating and profit margins of 14.58% and 5.87%.
Gross Margin | 43.33% |
Operating Margin | 14.58% |
Pretax Margin | 8.21% |
Profit Margin | 5.87% |
EBITDA Margin | 23.60% |
EBIT Margin | 14.58% |
FCF Margin | 18.41% |
Dividends & Yields
This stock pays an annual dividend of 0.69, which amounts to a dividend yield of 0.41%.
Dividend Per Share | 0.69 |
Dividend Yield | 0.41% |
Dividend Growth (YoY) | -52.08% |
Years of Dividend Growth | 3 |
Payout Ratio | 41.78% |
Buyback Yield | -3.60% |
Shareholder Yield | -3.19% |
Earnings Yield | 1.00% |
FCF Yield | 3.08% |
Stock Splits
The last stock split was on May 6, 2016. It was a forward split with a ratio of 6.
Last Split Date | May 6, 2016 |
Split Type | Forward |
Split Ratio | 6 |
Scores
Sartorius Stedim Biotech has an Altman Z-Score of 3.98.
Altman Z-Score | 3.98 |
Piotroski F-Score | n/a |